Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using pati...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/5/1181 |
| _version_ | 1797501293018742784 |
|---|---|
| author | Tao Wang Desirée Denman Silvia M. Bacot Gerald M. Feldman |
| author_facet | Tao Wang Desirée Denman Silvia M. Bacot Gerald M. Feldman |
| author_sort | Tao Wang |
| collection | DOAJ |
| description | While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using patient blood samples to assess immunotherapeutic responsiveness suggests a promising approach to the identification of novel and/or improved biomarkers for anti-PD-(L)1 immunotherapy. In this review, we discuss the advances in our evolving understanding of the regulation and function of PD-L1 expression, which is the foundation for developing blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy. We further discuss current knowledge and clinical study results for biomarker identification using PD-L1 expression on tumor and immune cells, exosomes, and soluble forms of PD-L1 in the peripheral blood. Finally, we discuss key challenges for the successful development of the potential use of blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy. |
| first_indexed | 2024-03-10T03:16:18Z |
| format | Article |
| id | doaj.art-2d0d5a5f01224811a7d1dcd2da90d438 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T03:16:18Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-2d0d5a5f01224811a7d1dcd2da90d4382023-11-23T10:12:14ZengMDPI AGBiomedicines2227-90592022-05-01105118110.3390/biomedicines10051181Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 ImmunotherapyTao Wang0Desirée Denman1Silvia M. Bacot2Gerald M. Feldman3Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USAOffice of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USAOffice of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USAOffice of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USAWhile promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using patient blood samples to assess immunotherapeutic responsiveness suggests a promising approach to the identification of novel and/or improved biomarkers for anti-PD-(L)1 immunotherapy. In this review, we discuss the advances in our evolving understanding of the regulation and function of PD-L1 expression, which is the foundation for developing blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy. We further discuss current knowledge and clinical study results for biomarker identification using PD-L1 expression on tumor and immune cells, exosomes, and soluble forms of PD-L1 in the peripheral blood. Finally, we discuss key challenges for the successful development of the potential use of blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy.https://www.mdpi.com/2227-9059/10/5/1181immune checkpoint inhibitoranti-PD-(L)1 immunotherapyliquid biopsybiomarkerPD-1PD-L1 |
| spellingShingle | Tao Wang Desirée Denman Silvia M. Bacot Gerald M. Feldman Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy Biomedicines immune checkpoint inhibitor anti-PD-(L)1 immunotherapy liquid biopsy biomarker PD-1 PD-L1 |
| title | Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy |
| title_full | Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy |
| title_fullStr | Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy |
| title_full_unstemmed | Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy |
| title_short | Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy |
| title_sort | challenges and the evolving landscape of assessing blood based pd l1 expression as a biomarker for anti pd l 1 immunotherapy |
| topic | immune checkpoint inhibitor anti-PD-(L)1 immunotherapy liquid biopsy biomarker PD-1 PD-L1 |
| url | https://www.mdpi.com/2227-9059/10/5/1181 |
| work_keys_str_mv | AT taowang challengesandtheevolvinglandscapeofassessingbloodbasedpdl1expressionasabiomarkerforantipdl1immunotherapy AT desireedenman challengesandtheevolvinglandscapeofassessingbloodbasedpdl1expressionasabiomarkerforantipdl1immunotherapy AT silviambacot challengesandtheevolvinglandscapeofassessingbloodbasedpdl1expressionasabiomarkerforantipdl1immunotherapy AT geraldmfeldman challengesandtheevolvinglandscapeofassessingbloodbasedpdl1expressionasabiomarkerforantipdl1immunotherapy |